| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5273421
Max Phase: Preclinical
Molecular Formula: C32H39NO3
Molecular Weight: 485.67
Associated Items:
Representations
Canonical SMILES: CCCCCCCCCCCC1=C(O)C(=O)C2=C(Nc3ccccc3C2c2ccc(C)c(C)c2)C1=O
Standard InChI: InChI=1S/C32H39NO3/c1-4-5-6-7-8-9-10-11-12-16-25-30(34)29-28(32(36)31(25)35)27(23-19-18-21(2)22(3)20-23)24-15-13-14-17-26(24)33-29/h13-15,17-20,27,33,35H,4-12,16H2,1-3H3
Standard InChI Key: JLYGVVIIOSDZRW-UHFFFAOYSA-N
Associated Targets(Human)
MCF7 126967 Activities
Associated Targets(non-human)
J774.A1 2436 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
H9c2 3506 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mitogen-activated protein kinase 1 and 3 (ERK2 and ERK1) 27 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 485.67 | Molecular Weight (Monoisotopic): 485.2930 | AlogP: 8.00 | #Rotatable Bonds: 11 |
| Polar Surface Area: 66.40 | Molecular Species: ACID | HBA: 4 | HBD: 2 |
| #RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 5.94 | CX Basic pKa: | CX LogP: 8.71 | CX LogD: 7.24 |
| Aromatic Rings: 2 | Heavy Atoms: 36 | QED Weighted: 0.25 | Np Likeness Score: 0.37 |
References
| 1. Martín-Acosta P, Cuadrado I, González-Cofrade L, Pestano R, Hortelano S, de Las Heras B, Estévez-Braun A.. (2023) Synthesis of Quinoline and Dihydroquinoline Embelin Derivatives as Cardioprotective Agents., 86 (2.0): [PMID:36749898] [10.1021/acs.jnatprod.2c00924] |
Source
Source(1):